display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - PDL1 positive
atezolizumab alone IMpower-110 ... IMpower-110 ... IMpower-110 ...

Study type: